<DOC>
	<DOCNO>NCT01347554</DOCNO>
	<brief_summary>Most previous data regard efficacy everolimus-eluting stent ( EES ) derive study compare EES bare metal stent ( BMS ) EES paclitaxel-eluting ( PES ) . Although sirolimus-eluting stent ( SES ) show efficacious drug regard inhibition neointima late loss , previous head head comparison EES zotarolimus-eluting stent ( ZES ) . Both everolimus sirolimus macrocyclic lactones target mTOR ( mammalian target rapamycin ) reduce vascular smooth muscle proliferation vessel injury therefore principle may show similar result stenting human . Data pool EES arm receive follow angiography SPIRIT III trial SES arm SIRIUS trial show similar rate binary restenosis late loss . However , stent polymer platform EES ZES report EES system thin stent + polymer thickness ( 88.6um ) previously KFDA-approved drug-eluting stent ( DES ) . In addition , data available efficacy EES ZES `` real world '' lesion select lesion study previous trial , acute myocardial infarction .</brief_summary>
	<brief_title>Efficacy Everolimus-Eluting Versus Zotarolimus-Eluting Sten Coronary Lesions Acute Myocardial Infarction</brief_title>
	<detailed_description>Previous randomize trial show efficacy slow-release polymeric sirolimus-eluting stent ( CYPHER , Cordis , Warren , NJ , USA ) , paclitaxel-eluting stent ( TAXUS , Boston Scientific , Natick , MA , USA ) , zotarolimus-eluting stent ( Endeavor , Medtronic , Minneapolis , MN , USA ) bare metal stent reduce neointimal hyperplasia , late luminal loss , angiographic restenosis lead decreased target lesion revascularization . The everolimus-eluting stent ( XIENCE V , Abott Vascular , Santa Clara , CA , USA , PROMUS , Boston Scientific , Natick , MA , USA ) newly develop drug elute stent use MULTILINK VISION® stent platform combine drug everolimus contain polymer coating . In first-in-man SPIRIT First clinical trial , XIENCE V show significant benefit bare metal VISION stent . Compared late loss 0.85 ± 0.36mm VISION arm , XIENCE V reduce late loss 88 % ( 0.10 ± 0.23mm ) . Also clinical safety XIENCE V confirm 6-month MACE rate 7.7 % . In SPIRIT II clinical trial , compare efficacy safety XIENCE V stent versus TAXUS PECSS stent , primary endpoint meet show non-inferiority XIENCE V compare TAXUS regard in-stent late loss 180 day . Actually , XIENCE V superior TAXUS reduce in-stent late loss 72 % mean 0.36 mm 0.11 mm . In addition , analysis key clinical endpoint show low rate ischemia drive MACE ( 2.7 % vs. 6.5 % XIENCE V vs. TAXUS ) protocol-defined stent thrombosis ( 0.5 % vs. 1.3 % XIENCE V vs. TAXUS ) . The low rate ischemia drive MACE 180 day sustain 1 year new instance late stent thrombosis either group 1 year . The SPIRIT III RCT prospective , 2:1 randomize , active-controlled , single blind , parallel , multi-center clinical evaluation XIENCE V Everolimus Eluting Coronary Stent System ( XIENCE V EECSS ) compare TAXUS Paclitaxel Eluting Coronary Stent System ( TAXUS PECSS ) treatment two de novo lesion . This pivotal clinical trial design demonstrate non-inferiority XIENCE V EECSS TAXUS PECSS . Patients randomize 2:1 XIENCE V TAXUS primary endpoint in-segment late loss 240 day . The result show mean in-segment late loss 0.14mm XIENCE V 0.28 mm TAXUS ( p &lt; 0.001 non-inferiority , p=0.0037 superiority ) . The secondary endpoint , ischemia-driven target vessel failure ( TVF ) , 7.6 % XIENCE V 9.7 % TAXUS , confirm non-inferiority XIENCE V. Furthermore , rate definite probable stent thrombosis 1.1 % 0.6 % XIENCE V TAXUS , respectively . With recent approval new DES , zotarolimus-eluting stent ( Endeavor , Medtronic , Minneapolis , MN ) , comparison study conduct compare Endeavor zotarolimus-eluting stent sirolimus-eluting stent paclitaxel-eluting stent . zotarolimus sirolimus share common structural biological property . In vitro data suggest sirolimus tetrazole contain rapamycin analog similar inhibitory effect mixed lymphocyte reaction assay . The ENDEAVOR clinical trial currently progress evaluate phosphoryl choline ( PC ) -coated zotarolimus-eluting stent ( ZES ) prevention restenosis . The Endeavor zotarolimus-eluting stent utilizes cobalt alloy balloon-expandable stent ( Driver ; Medtronic ) geometry similar stainless steel stent use preliminary study ( S7 ; Medtronic ) . The Endeavor ZES also employee PC strut surface coat drug delivery reservoir dose 10 g/mm ABT-578 . The Endeavor ( ZES ) , however , differs stent use experimental study addition drug-free PC topcoat serve diffusion barrier retard drug release polymer reservoir . Angiographic analysis 4 month 100-patient focal de novo lesion ENDEAVOR I feasibility study demonstrate mean in-stent percent diameter stenosis approximately 14 % late lumen loss 0.3 mm low frequency target lesion revascularization ( 1 % ) . The clinical outcome ENDEAVOR II ( 1,500 patient randomize ABT-578 bare metal stent ) ENDEAVOR III ( 436 patient randomize 3:1 ABT-578 Cypher ) trial well ongoing study show efficacy PC-coated ABT-578-eluting stent . In ENDEAVOR III study , Endeavor stent large late loss high binary restenosis analysis segment stented segment . Most previous data regard efficacy EES derive study compare EES BMS EES PES . Although sirolimus elute stent ( SES ) show efficacious drug elute stent regard inhibition neointima late loss , previous head head comparison EES ZES . Both everolimus sirolimus macrocyclic lactones target mTOR ( mammalian target rapamycin ) reduce vascular smooth muscle proliferation vessel injury therefore principle may show similar result stenting human . Data pool EES arm receive follow angiography SPIRIT III trial SES arm SIRIUS trial show similar rate binary restenosis late loss . However , stent polymer platform EES ZES report EES system thin stent + polymer thickness ( 88.6um ) previously KFDA-approved DES . In addition , data available efficacy EES ZES `` real world '' lesion select lesion study previous trial , acute myocardial infarction .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age &gt; 18 year Chest pain duration 10 minute At least follow criterion A. ECG change ( T inversion , ST depression ST elevation ) B. Cardiac enzyme elevation upper normal limit Significant coronary artery stenosis ( &gt; 50 % visual estimate ) The patient guardian agree study Stent thrombosis Left main disease Cardiogenic shock Cronic kidney disease renal failure require hemodialysis History bleeding diathesis know coagulopathy Gastrointestinal genitourinary bleeding within prior 3 month History major surgery within 2 month Planned surgery require cessation clopidogrel within 12 month percutaneous coronary intervention ( PCI ) Serious patient whose life expectancy &lt; 1 year severe infectious status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>everolimus</keyword>
	<keyword>zotarolimus</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>MACE</keyword>
	<keyword>safety</keyword>
</DOC>